Insights That Move the GPCR Field Forward

Drug discovery is built on a seductive simplification: identify the malfunctioning receptor, design a compound that engages it, and restore function. But many diseases don't cooperate with that assumption. Alzheimer's, metabolic disease, psychiatric pharmacology — each carries evidence of multi-receptor architecture. Multi-target GPCR pharmacology is not a workaround. In certain disease architectures, it is the pharmacologically correct approach.

The A₂A adenosine receptor NanoBRET® competitive binding assay enables real-time quantification of ligand–receptor interactions in living cells. By combining NanoLuc-tagged receptors with fluorescent tracers, this approach allows direct measurement of binding displacement, delivering robust pIC₅₀ and pKᵢ values that align with established pharmacology. In this article, we examine the assay principle, validation strategy, and performance across reference antagonists and agonis